

MEASURING CHANGE

in HR+/HER2– mBC

The impact of CDK4/6 inhibitors

Saturday, 9 September 2017, 13:00–14:30
Sevilla Auditorium, Hall 9, IFEMA - Feria de Madrid, Madrid, Spain

Dear Colleague,

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium **‘Measuring change in HR+/HER2– mBC: The impact of CDK4/6 inhibitors’**. The symposium will be held on **Saturday, 9 September**, from **13:00 to 14:30**, during the ESMO 2017 Congress.

Knowledge and clinical experience in the management of HR+/HER2– metastatic breast cancer (mBC) are rapidly evolving. CDK4/6 inhibitors represent a major advance in this disease setting and are now an important treatment option for patients with HR+/HER2– mBC. As our clinical experience with these therapies continues to expand, we are beginning to see how data from clinical trials of CDK4/6 inhibitors are reflected in the real world.

During this symposium, my colleagues and I will review how CDK4/6 inhibitors are changing clinical practice today and will explore how the preclinical molecular footprint of CDK4/6 inhibition translates into clinical outcomes. Throughout, we will share our experience of incorporating this new treatment option into the clinic, including key considerations for therapy management.

I look forward to welcoming you in Madrid for what promises to be an exciting and informative symposium as we consider the new road ahead of us in the management of HR+/HER2– mBC.



Eva Ciruelos, Chair

Medical Oncologist, Hospital 12 de Octubre
Madrid, Spain

PROGRAMME

Chair: Eva Ciruelos (Spain)

13:00–13:15

Making strides in the current landscape and beyond

Eva Ciruelos

13:15–13:35

The benefits of CDK4/6 inhibitors for patients with mBC: a molecular footprint

Peter Schmid (UK)

13:35–13:55

The benefits of CDK4/6 inhibitors for patients with mBC: a clinical footprint

Nicholas Turner (UK)

13:55–14:15

Advances in therapy management and experience from the clinic: the road ahead

Marc Thill (Germany)

14:15–14:30

Q&A and closing remarks

All faculty

*Lunch boxes will be available
prior to the symposium*



This meeting is organised and funded by Pfizer.
© 2017 Pfizer Pharma GmbH. All rights reserved.
July 2017. PP-IBR-EUR-0514

